GlassScriptPhysician profile
Emilee Odom
NPI 1417306580
$7,319.49
in general payments reported to CMS, 2019-2025
23 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $1,505 · 2023: $1,625 · 2024: $1,671 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.47 |
| Education | $115.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,934.74 | 2021-2025 | |
| Lilly USA, LLC | $922.05 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $797.15 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $646.00 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $547.46 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $449.24 | 2021-2025 | Tremfya |
| Genzyme Corporation | $402.17 | 2021-2025 | |
| Leo Pharma INC. | $390.34 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $320.17 | 2021-2025 | Ilumya |
| Incyte Corporation | $192.91 | 2022-2024 | Opzelura |
| Pfizer INC. | $180.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.70 | 2021-2025 | Dupixent, Libtayo |
| Organon LLC | $69.70 | 2025 | Hadlima, Vtama |
| Organogenesis INC. | $60.86 | 2022-2023 | Puraply |
| Amgen INC. | $48.06 | 2022-2023 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.86 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.49 | 2024-2025 | Cabtreo, Arazlo |
| Journey Medical Corporation | $26.03 | 2022 | |
| Kyowa Kirin, INC. | $25.76 | 2021 | |
| Genentech USA, INC. | $25.34 | 2024 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $17.56 | 2024 | Valchlor |
| Dermira, INC. | $15.29 | 2021 | |
| Dermavant Sciences, INC. | $13.57 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilee Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.